Medical Therapy of Glaucoma: New Targets and Drug Combinations

Released On
October 1, 2019

Expires On
October 1, 2020

Media Type

Completion Time
60 minutes

Ophthalmology, Glaucoma Specialists

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and iVista Medical Education, Inc.


Supported by an educational grants from Aerie Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended to meet the needs of ophthalmologists and glaucoma specialists.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the risk factors for glaucoma and the impact of increased intraocular pressure (IOP) on patient outcomes
  • Discuss the current use of existing and novel pharmacotherapies for patients with open angle glaucoma
  • Evaluate the clinical trials results of newly approved ocular hypotensive agents, including ROCK inhibitors and combination agents
  • Discuss the mechanisms of action of the new and emerging medications and the novel medication targets within the trabecular meshwork (TM)
  • Evaluate the clinical trials results of newly approved ocular hypotensive agents, including ROCK inhibitors and combination agents
  • Review strategies for setting patient expectations and improving patient compliance with glaucoma therapy


Leon W. Herndon, Jr., MD (Chair and Moderator)

Professor of Ophthalmology
Chief, Glaucoma Division
Duke Eye Center
Durham, NC

Jonathan S. Myers, MD

Chief, Glaucoma Service
Wills Eye Institute
Philadelphia, PA

Arthur J. Sit, MD

Professor of Ophthalmology
Vice Chair, Clinical Practice
Glaucoma Fellowship Director
Department of Ophthalmology
Mayo Clinic
Rochester, MN

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and iVista Medical Education, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Disclosures of Conflicts of Interest

Leon W. Herndon, Jr., MD – Course Director

  • Consultant: Aerie Pharmaceuticals, Inc.

Jonathan S. Myers, MD

  • Consultant: Aerie Pharmaceuticals, Inc.; Allergan; Glaukos Corp; MicroOptx
  • Contracted Research: Aerie Pharmaceuticals, Inc.; Alcon; Allergan; Carl ZEISS Meditec, Inc.; Diopsys, Inc.; Glaukos Corp; Haag-Streit Group; Heidelberg Engineering Inc.; Merck & Co.; Novartis
  • Speakers Bureau: Aerie Pharmaceuticals, Inc.; Allergan

Arthur J. Sit, MD

  • Consultant: Aerie Pharmaceuticals Inc.; Allergan Inc.; Injectsense Inc.; PolyActiva Pty
  • Contracted Research: Aerie Pharmaceuticals, Inc.

Planner Disclosures

Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations, nothing to disclose.

iVista Staff and Planners, nothing to disclose.

AKH Planners and Reviewers, nothing to disclose.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation and Credit

In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. If you have questions about this CME activity, please contact AKH Inc. at

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.